基因工程抗体中噬茵体抗体库技术的应用

通过基因工程可以大规模地制备能与人相容的单克隆抗体或片段.其中,噬茵体抗体库技术可以模拟体内抗体产生和成熟过程,不经细胞杂交,甚至不经免疫制备针对任何抗原的单克隆抗体.就基因工程抗体及噬茵体抗体库技术的发展与应用作一概述.     

Interaction of thyroid-stimulating antibody with Graves' thyroid-stimulating hormone-binding antibody

OBJECTIVE: Evidence of anti-thyroid-stimulating hormone (TSH) antibody in Graves' serum has been reported. We found that extremely high Graves' anti-TSH antibodies neutralized other Graves' thyroid-stimulating antibody (TSAb) activity. METHOD: TSAb-IgG was affinity-purified by Sepharose-bound Graves' anti-TSH antibody (extremely high). RESULT: The thyroid-stimulating activity in affinity-purified TSAb-IgG increased about 4-5 times compared to that before purification. TSH-binding inhibitory immunoglobulin (TBII) activity in affinity-purified TSAb-IgG also increased using TSH receptor-coated tube assay. A similar increase of thyroid-stimulating activity accompanied with TBII activity was also observed in affinity-purified TSAb-IgG-F(ab')(2). CONCLUSION: This suggests the possibility that either TSAb may be an anti-idiotypic antibody against anti-TSH antibody or anti-TSH antibody may be an anti-idiotypic antibody against anti-TSH receptor antibody.     

基因工程抗体中噬菌体抗体库技术的应用

通过基因工程可以大规模地制备能与人相容的单克隆抗体或片段。其中,噬菌体抗体抗库技术可以模拟体内抗体产生和成熟过程,不经细胞杂交,甚至不经免疫制备针对任何抗原的单克隆抗体。就基因工程抗体及噬菌抗体库技术的发展与应用作一概述 。     

Determination of antibody affinity by using antigenic and antibody immunosorbents

To determine the affinity of the active centers of antibodies, cellulose immunosorbents for antibodies and antigens have been used. The fixation of serum proteins on the sorbent, the interaction of fixed antibodies with a monovalent antigen and the graphic analysis of the results thus obtained allows one to assess not only the concentration of the effective active centers on the sorbent, but also all known characteristics of antibody affinity: the average association constant K0, the common association constant Kt, the geometric association constant Kg, the average association constants which determine the affinity of different antibody groups. The use of antigenic immunosorbent permits one to determine the value of the average internal association constant K0. The determination of antibody affinity in hyperimmune antiplague sera by means of immunosorbents and red blood cells coated with capsular antigen has resulted in obtaining similar values of affinity indices.     

Human monoclonal antibody

Summary A human clone was derived from fusion of a malignant cell line (Ball-1) and peripheral blood lymphocytes from a breast cancer patient in long-term remission. This clone, JDB1, was shown to be a genetically identifiable hybrid, expressing chromosomes unique to each of the parental cell types. The JDB1 clone produces IgG/lambda molecules which are extremely reactive with breast tumor cells, but do not bind to normal breast tissue or other types of malignant tissue. This hybrid was constructed without using the commonly accepted fusion technology which employs 8-azoguanine resistant HAT sensitive malignant fusion partners. Rather a selective fusion procedure was used in which a choice of the most efficient and effective malignant partner could be made prior to fusion. This approach was accompanied by stringent selection of patients as lymphocyte donors. This method has allowed for stable and vigorous growth of clones with a near constant amount of specific immunoglobulin production and a normal diploid chromosome number for over 3 years.     

Tailor-made antibody therapeutics

Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical industry. There are currently 18 monoclonal antibodies in the market that have been approved by the FDA and over 150 in clinical developments. Driven by innovation and technological developments, scientists have gone beyond the traditional antibody molecules. Antibodies have been engineered in a variety of ways to meet the challenges posed by different biological settings. Described in this review is an abridged account of the different ways antibodies have been tailored to make them efficient drug molecules.     

Crystalline pneumococcus antibody

1. The immune precipitate formed by antipneumococcus horse serum and the specific polysaccharide is not hydrolyzed by trypsin as is the diphtheria toxin-antitoxin complex, and purified pneumococcus antibody cannot be isolated by the method used for the isolation and crystallization of diphtheria antitoxin. 2. Type I pneumococcus antibody, completely precipitable by Type I polysaccharide, may be obtained from immune horse serum globulin by precipitation of the inert proteins with acid potassium phthalate. 3. The antibody obtained in this way may be fractionated by precipitation with ammonium sulfate into three main parts. One is insoluble in neutral salts but soluble from pH 4.5 to 3.0 and from pH 9.5 to 10.5. This is the largest fraction. A second fraction is soluble in 0.05 to 0.2 saturated ammonium sulfate and the third fraction is soluble in 0.2 saturated ammonium sulfate and precipitated by 0.35 saturated ammonium sulfate. The second fraction can be further separated by precipitation with 0.17 saturated ammonium sulfate to yield a small amount of protein which is soluble in 0.17 saturated ammonium sulfate but insoluble in 0.25 saturated ammonium sulfate. This fraction crystallizes in poorly formed, rounded rosettes. 4. The crystallization does not improve the purity of the antibody and is accompanied by the formation of an insoluble protein as in the case of diphtheria antitoxin. 5. None of the fractions obtained is even approximately homogeneous as determined by solubility measurements. 6. Purified antibody has also been obtained by dissociating the antigen-antibody complex. 7. The protective value of the fractions is quite different; that of the dissociated antibody being the highest and that of the insoluble fraction, the lowest. 8. All the fractions are immunologically specific since they do not precipitate with Type II polysaccharide nor protect against Type II pneumococci. 9. All the fractions give a positive precipitin reaction with antihorse rabbit serum. The dissociated antibody gives the least reaction. 10. Comparison of the various fractions, either by their solubility in salt solution or through immunological reactions, indicates that there are a large number of proteins present in immune horse serum, all of which precipitate with the specific polysaccharide but which have very different protective values, different reactions with antihorse rabbit serum, and different solubility in salt solutions.